• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

Havn Life CEO to Present at Zooming With LD, a Leading Platform for Microcap Companies

Microdose by Microdose
March 19, 2021
in Press Releases
Reading Time: 3 mins read
A A

CEO Tim Moore will appear on Tuesday, March 24th at 8:00 AM PT/ 11:00 AM ET


Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, announced today that it will be presenting virtually at the upcoming Zooming with LD event on Wednesday, March 24th 2020 at 8:00 AM PT/11:00 AM ET.

Tim Moore, Chief Executive Officer of Havn Life, will give a 1-hour presentation to this audience of investors and media. Afterwards, Moore will be available for 1:1 meetings with attendees, offering an exclusive opportunity to ask questions and discuss Havn Life’s business with the CEO. Founded in 2006, LD Micro is a leading, independent resource for the microcap world, curating events like Zooming With LD to connect the investment community with business leaders in the microcap space.

WHO:              Tim Moore, Havn Life Sciences CEO

[bsa_pro_ad_space id=2]
ADVERTISEMENT

WHEN:            Wednesday, March 24th 2020 at 8:00 AM PT/11:00 AM ET

Continue on your trip...

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

Enveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment

WHERE:          Investors and other individuals may access the virtual presentation by registering here:

https://us02web.zoom.us/webinar/register/WN_WwKAg8NzRPqULf2w-UZqog

Chris Lahiji, Founder of LD Micro and host of Zooming With LD, noted “Psychedelic medicine has the potential to be a game-changer for millions of people around the world. At LD Micro, we are always eager to give a platform to unique, forward-thinking companies. Havn Life is bringing a truly new vision to biotech and natural healthcare products.”

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

Lasix Direct Sale Online


About Havn Life Sciences Inc.

Havn Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram and Youtube.

Connect

Investor Relations
ir@havnlife.com
(604) 687-7130

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife

Media Contact
savi@emergence-creative.com
(647) 896-8078

[bsa_pro_ad_space id=2]
ADVERTISEMENT

The post Havn Life CEO to Present at Zooming With LD, a Leading Platform for Microcap Companies appeared first on HAVN Life.

Learn more about the psychedelics industry at Microdose.

Tags: Havn Life
Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Next Post

Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.